Using a small Randomized Controlled Trial (RCT) study design, PNPLA3 risk allele carriers (CG/GG genotype) with NAFLD, will be assigned 2:1 to a tailored NAFLD-specific weight loss intervention compared to a wait-list control group.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Study Recruitment: Interest in Participation at Baseline
Timeframe: Baseline
Study Recruitment: Screened for Eligibility at Baseline
Timeframe: Baseline
Study Recruitment: Eligibility at Baseline
Timeframe: Baseline
Study Recruitment: Enrollment at Baseline
Timeframe: Baseline
Retention at 6-months
Timeframe: 6-months
Retention at 12-months
Timeframe: 12-months
Attendance at weekly counseling sessions at 6-months
Timeframe: 6-months
Attendance at weekly counseling sessions at 12-months
Timeframe: 12-months
Self-monitoring of dietary intake at 6-months
Timeframe: 6-months
Self-monitoring of dietary intake at 12-months
Timeframe: 12-months
Self-monitoring of physical activity at 6-months
Timeframe: 6-months
Self-monitoring of physical activity at 12-months
Timeframe: 12-months
Self-weighing behaviors at 6-months
Timeframe: 6-months
Self-weighing behaviors at 12-months
Timeframe: 12-months
Intervention delivery time at 6-months
Timeframe: 6-months
Intervention delivery time at 12-months
Timeframe: 12-months
Treatment Satisfaction at 6-months: rating
Timeframe: 6-months
Treatment Satisfaction at 12-months: rating
Timeframe: 12-months